Watching Protara Therapeutics, Opthea Ltd.; Shares Moving Higher As Traders Circulate Post From 'TipRanks' Suggesting "These 2 'Strong Buy' Penny Stocks Could Surge Over 400%, Says Oppenheimer"
Watching Protara Therapeutics, Opthea Ltd.; Shares Moving Higher As Traders Circulate Post From 'TipRanks' Suggesting "These 2 'Strong Buy' Penny Stocks Could Surge Over 400%, Says Oppenheimer"
Opthea Announces Upcoming Presentations at the Retina World Congress 2024
MELBOURNE, Australia and PRINCETON, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, the "Company")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent
Opthea Showcases Retinal Disease Therapy Advances
Opthea Advances Pivotal Trials for Eye Disease Drug
Opthea to Present at the OIS Retina Innovation Summit at ARVO
MELBOURNE, Australia and PRINCETON, N.J., April 25, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, the "Company")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent
Opthea Limited Issues New Contractor Options
Owning 39% Shares,institutional Owners Seem Interested in Opthea Limited (ASX:OPT),
Opthea Hires New VP to Advance Retinal Therapies
Opthea Appoints John Han, PharmD, as VP Medical Affairs
MELBOURNE, Australia and PRINCETON, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, the "Company")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent
Analysts Offer Insights on Healthcare Companies: Universal Health (UHS), Ultragenyx Pharmaceutical (RARE) and Opthea Limited Sponsored ADR (OPT)
Opthea Limited Foresees Visionary Breakthroughs
Opthea to Participate in the 23?? Annual Needham Virtual Healthcare Conference
Opthea Limited Announces Director's Resignation and Final Interests
Opthea Limited Welcomes New Director
Why A2 Milk, Lindsay Australia, Meridian Energy, and Opthea Shares Are Falling Today
Opthea Bolsters Board With Biopharmaceutical Expertise
Opthea Limited Foresees Growth in Vision Therapy
Press Release: Opthea Appoints Sujal Shah to the Board of Directors
Opthea Appoints Sujal Shah to the Board of Directors Former CymaBay Therapeutics CEO brings extensive leadership experience to his role as a Non-Executive Director and Audit and Risk Committee Chair
Opthea to Host Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degeneration on April 3, 2024
MELBOURNE, Australia and PRINCETON, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Opthea Limited ((ASX:OPT, NASDAQ:OPT, "Opthea")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly
Opthea to Participate in the Leerink Partners Global Biopharma Conference
MELBOURNE, Australia, March 05, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT; "Opthea"), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevale
No Data